27th January 2022

The British Society for Antimicrobial Chemotherapy (BSAC) is delighted to announce a new partnership with Pfizer, focussing on the development of centres of excellence for Antimicrobial Stewardship (AMS) practice, with the goal of reducing inequities in access to AMS programmes and improving patient outcomes.

Part of Pfizer Global Medical Grants (GMG) programme, this Request for Proposal (RFP) aims to solicit programs that have identified a resource limitation within their healthcare organization that impacts the establishment of a holistic and sustainable antimicrobial stewardship (AMS) program. The RFP will support delivery, to successful applicant institutions, of a programme of work to support the development of local AMS programs and will culminate with accreditation of centres and lead to a network of AMS Centres of Excellence across the world that can share learning within their region.

Tracey Guise, BSAC’s Chief Executive Officer, said:

“Antimicrobial resistance (AMR) is widely recognized as one of the biggest threats to global health today, with the potential to affect anyone, of any age, in any country. We are therefore excited to announce this ambitious programme, which will not only contribute to containment/reduction of AMR at local, national, and global level, but also make a significant, sustainable contribution to reducing disparities of access to effective and holistic AMS programmes, improve effective antimicrobial prescribing and deliver improved patient outcomes.”

Organizations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP, full details of which can be found here.

GP? Pharmacist? Researcher? Social Scientist? Whatever field you work in, if you’re committed to fighting infection then we want you to join us as a BSAC Member.
Become a member

Having trouble finding what you're after?